Takeda Research & Development Fact Sheet
At Takeda, we are a forward-looking, world-class R&D organization that unlocks innovation and delivers transformative therapies to patients. By focusing R&D efforts on four therapeutic areas and other targeted investments, we push the boundaries of what is possible in order to bring life-changing therapies to patients worldwide.

Our Focus Areas

**ONCOLOGY**
We endeavor to deliver novel medicines to patients with cancer worldwide through our three strategic pillars: hematology malignancies, lung cancer and immuno-oncology (I/O).

**RARE GENETICS AND HEMATOLOGY**
We aspire to bring transformative or curative therapies for rare genetic disorders including hematology, inborn errors of metabolism and lysosomal storage disorders.

**NEUROSCIENCE**
Our mission is to bring innovative and potentially disease-modifying medicines to patients with neurological and neuromuscular diseases of high unmet need.

**GASTROENTEROLOGY (GI)**
We work to restore Life to Living for patients suffering with GI diseases across our core disease areas: inflammatory bowel disease, celiac and other luminal gut diseases, motility disorders and liver diseases.

A Diverse & Dynamic Pipeline

<table>
<thead>
<tr>
<th>NEW MOLECULAR ENTITY CLINICAL-STAGE ASSETS</th>
<th>PIPELINE WITH ORPHAN DRUG DESIGNATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>~40</td>
<td>~50%</td>
</tr>
</tbody>
</table>

**MODALITY-DIVERSE RESEARCH PROJECTS**
Our Research engine is investing in next-generation technologies beyond small molecules to bring a new wave of innovative treatments to patients.

**PUTTING PATIENTS FIRST**
Takeda’s R&D patient access programs, knowledge sharing and capacity building programs have been recognized as *Industry Best Practices* by the Access to Medicine Foundation.

**R&D ESTABLISHED:**

| 20+ PARTNERSHIPS | 50+ INITIATIVES |

with non-governmental organizations since 2015 to support local R&D and healthcare capacity building in underserved countries and communities.

**EXTERNALLY ORIENTED MINDSET**
We seek innovation and partner to nurture it, wherever it resides. We have diverse partnership models, each created with aligned incentives and designed to leverage what we each do best - together.

Since FY16

| 200+ Active Partnerships |
| 45+ Venture Investment Financings |
| 25+ New Company Creations |

---

1 Pipeline as of October 29, 2020
© Takeda Pharmaceutical Company Limited. All rights reserved. November 2020.
Our Global Footprint

Regional Centers*

OSAKA, JAPAN
TOKYO, JAPAN
SHANGHAI, CHINA
SINGAPORE
ZÜRICH, SWITZERLAND
VIENNA & ORTH, AUSTRIA

*Each regional center also has a secondary support team in the general vicinity to support local regulatory engagement and sustain other R&D activities.

LOCAL SITES
Takeda operates in additional countries for specific R&D functions and/or based on legal requirements.

SAN DIEGO, CA
GI, Neuroscience, Discovery Technologies

SHONAN, JAPAN
Neuroscience, Takeda & the Center for IPS Cell Research & Application, iPark

BOSTON, MA
R&D Center, Oncology, GI, Rare Diseases

R&D Employees Globally

~5,000

R&D Leadership Team

Andy Plump
President, Research & Development

Chris Arendt
Head, Oncology Therapeutic Area Unit

Dan Curran
Head, Rare Genetics and Hematology Therapeutic Area Unit

Sarah Sheikh
Head, Neuroscience Therapeutic Area Unit

Asit Parikh
Head, Gastroenterology Therapeutic Area Unit

Steve Hitchcock
Head, Research

Nenad Grmusa
Head, Center for External Innovation

Georgia Keresty
R&D Chief Operating Officer

Wolfram Nothaft
Chief Medical Officer

Stefan Wildt
R&D Chief Technology Officer and Head, Pharmaceutical Sciences

Jeremy Chadwick
Head, Global Development Office

Anne Heatherington
Head, Data Sciences Institute

Wolfgang Hackel
Head, R&D Portfolio & Finance Strategy and Operations

Erika Marder
Head, Global R&D Human Resources

Colleen Beauregard
Head, R&D Sustainable Innovation and Life Sciences Leadership

Toshio Fujimoto
General Manager, Shonan Health Innovation Park (iPark)

© Takeda Pharmaceutical Company Limited. All rights reserved. November 2020.